[ONTX] Onconova Therapeutics, Inc.
Overview
Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
Market Capitalization:
Exchange: NASDAQ
The data is delayed by 15 minutes.
Strongest Trends Summary For ONTX
ONTX is in the medium-term down -67% in 1 year and down -87% in 1 year and down -93% in 1 year. In the long-term down -95% in 3 years and up 30069% in 22 years.
Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max
Chart type: absolute | relative to S&P
Description: Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule drug candidates to treat cancer. Its clinical-stage product candidates include rigosertib intravenous that is in Phase III trials for higher risk myelodysplastic syndromes (MDS); rigosertib Oral, which is Phase II clinical trials for patients with transfusion-dependent lower risk MDS and in patients with head and neck cancers; and a combination of rigosertib Oral and azacitidine in a Phase 1/2 study of first-line MDS patients. The company?s clinical-stage product candidates also comprise ON 013105, a small molecule targeting an important regulatory protein, cyclin D1, which is found at elevated levels in cancer cells; and recilisib, a molecule with radiation protection properties has completed four Phase I clinical trials. In addition, its preclinical products consist of ON 1231320, an inhibitor of polo-like kinase 2; ON 123300, an inhibitor of the cell cycle and cancer cell metabolism
See how to gain 20% in 14 sec with TrendsInvesting
Fundamental Ratios
| Shares Outstanding | EPS | EPS Growth - 4 Quarters | EPS Growth - Q/Q | ||||
| EPS Growth - Y/Y | Sales Growth - 4 Quarters | -8.8% | Sales Growth - Q/Q | 0% | P/E | ||
| P/E To EPS Growth | P/S | P/BV | Price/Cash Per Share | ||||
| Price/Free Cash Flow | ROA | -156.2% | ROE | -487.72% | ROI | ||
| Current Ratio | 3.38 | Quick Ratio | Long Term Debt/Equity | Debt Ratio | 0.92 | ||
| Gross Margin | Operating Margin | -12282.7% | Net Profit Margin | -12279.7% | Dividend Payout Ratio | ||
| Dividend Yield |
Fundamental Data
| Cash From Financing Activities | Cash From Investing Activities | Cash From Operating Activities | -9.85 M | Gross Profit | |||
| Net Profit | -12.34 M | Operating Profit | -12.35 M | Total Assets | 36.71 M | Total Current Assets | 36.35 M |
| Total Current Liabilities | 10.76 M | Total Debt | Total Liabilities | 24.95 M | Total Revenue | 110 K |
Technical Data
| High 52 week | 5.78 | Low 52 week | 0.3 | Last close | 0.3 | Last change | -24.58% |
| RSI | 26.62 | Average true range | 0.06 | Beta | 0.13 | Volume | 18.76 K |
| Simple moving average 20 days | -37.42% | Simple moving average 50 days | -66.09% | Simple moving average 200 days | -88.69% |
Performance Data
| Performance Week | -16.19% | Performance Month | -64.92% | Performance Quart | -86.53% | Performance Half | -90.77% |
| Performance Year | -92.55% | Performance Year-to-date | -85.7% | Volatility daily | 10.4% | Volatility weekly | 23.26% |
| Volatility monthly | 47.67% | Volatility yearly | 165.14% | Relative Volume | 157.7% | Average Volume | 426.28 K |
| New High | New Low |
News
2020-08-03 11:52:03 | Onconova ONTX to Report Q2 Earnings: What's in the Offing?
2020-07-29 13:30:00 | Onconova Therapeutics Announces that the Required Number of Survival Events Has Been Reached for the Pivotal Phase 3 INSPIRE Trial Data Analysis
2020-07-27 08:00:00 | Onconova Therapeutics Submits Application for Rigosertib to Participate in Federally Funded Human Studies in COVID-19 Disease
2020-07-23 08:00:00 | Onconova Therapeutics Announces Publication of Preclinical Data Supporting Rigosertib’s Mechanism of Action as a Targeted Anticancer Therapy
2020-07-07 08:00:10 | Onconova Therapeutics Announces Publication of Phase 1 Results in Leukemia Research Exploring Oral Rigosertib in Combination with Azacitidine in Higher-Risk MDS
2020-06-23 10:43:02 | Onconova Initiates Phase I/IIa Study on Lung Cancer Candidate
2020-06-23 08:00:10 | Onconova Therapeutics Announces Participation in Noble Capital Markets Investor Webinar
2020-06-22 08:00:10 | Onconova Therapeutics Announces the Initiation of a Phase 1/2a Study of Rigosertib plus Nivolumab for the Treatment of KRAS+ Lung Adenocarcinoma
2020-06-12 08:00:10 | Onconova Therapeutics Announces Presentation at the 25th Congress of the European Hematology Association EHA
2020-06-08 08:00:10 | Onconova Therapeutics Announces Presentation at BIO Digital 2020
2020-05-28 09:44:06 | 3 “Strong Buy” Penny Stocks That Offer Massive Potential Gains
2020-05-18 11:33:58 | Edited Transcript of ONTX earnings conference call or presentation 14-May-20 8:30pm GMT
2020-05-14 16:05:10 | Onconova Therapeutics Provides Corporate Update and Reports First Quarter 2020 Financial Results
2020-05-11 08:00:10 | Onconova Therapeutics Announces Virtual Format for 2020 Annual Meeting of Stockholders
2020-05-07 08:00:10 | Onconova Therapeutics to Provide Corporate Update and First Quarter 2020 Earnings on May 14, 2020
2020-04-27 08:00:10 | Onconova Therapeutics Strengthens Board of Directors with Nomination of Life Sciences Industry Veteran
2020-04-07 06:40:00 | How 3 Philly-area biopharmaceutical firms are working through coronavirus challenges
2020-04-01 07:32:15 | Edited Transcript of ONTX earnings conference call or presentation 24-Mar-20 8:30pm GMT
2020-03-24 16:05:10 | Onconova Therapeutics Announces Completion of Enrollment of Phase 3 INSPIRE Trial, Provides a Corporate Update, and Reports 2019 Financial Results
2020-03-18 08:00:10 | Onconova Therapeutics to Provide Corporate Update and Full Year 2019 Financial Results
2020-03-13 09:46:01 | Will Onconova Therapeutics Continue to Surge Higher?
2020-03-02 09:54:02 | Onconova ONTX to Report Q4 Earnings: What's in Store?
2020-02-21 10:12:03 | The Zacks Analyst Blog Highlights: Onconova Therapeutics, Abeona Therapeutics, Proteostasis Therapeutics, Applied Therapeutics and Ennis
2020-02-20 08:45:01 | Onconova Therapeutics, Inc. ONTX Shares March Higher, Can It Continue?
2020-02-20 07:03:12 | US Dollar Flexes Muscles Against Other Currencies: 5 Winners
2020-02-19 11:19:04 | The Zacks Analyst Blog Highlights: Apple, Eagle Bancorp Montana, Onconova Therapeutics, Proteostasis Therapeutics and Abeona Therapeutics
2020-02-18 09:21:02 | Coronavirus to Hit Apple Sales: Invest in Domestic Producers
2020-02-18 08:00:10 | Onconova Therapeutics Announces Participation in Two Upcoming International Conferences
2020-02-10 08:00:10 | Onconova Therapeutics to Present Update at Noble Capital Markets’ Sixteenth Annual Investor Conference in Hollywood, FL
2020-02-04 08:00:10 | Onconova Therapeutics to Present Update at the 2020 BIO CEO & Investor Conference in New York City
2020-01-23 17:44:40 | Onconova shares rise after company regains rights to drug in China
2020-01-23 08:30:10 | Onconova Therapeutics Regains Rigosertib Rights in Greater China
2020-01-03 13:27:41 | Onconova Therapeutics, Inc. Announces Closing of $10 Million Registered Direct Offering of Common Stock Priced At-The-Market
2020-01-02 13:48:43 | Bucks County biopharm firm plans $10M stock sale
2019-12-31 11:30:10 | Onconova Therapeutics, Inc. Announces $10 Million Registered Direct Offering Priced At-The-Market
2019-12-23 19:33:30 | Onconova Therapeutics, Inc. ONTX Is Burning These Hedge Funds
2019-12-19 13:44:55 | Onconova Therapeutics, Inc. Announces Closing Of $5.0 Million Registered Direct Offering Priced At-The-Market
2019-12-18 09:05:10 | Onconova Therapeutics, Inc. Announces $5.0 Million Registered Direct Offering Priced At-the-Market
2019-12-18 09:00:10 | Onconova Therapeutics Announces Exclusive License Agreement with Specialised Therapeutics for Rigosertib in Australia and New Zealand
2019-12-17 07:30:10 | Onconova Therapeutics and Pint Pharma Announce Brazilian Health Authority Approval for Initiating INSPIRE Trial with Intravenous Rigosertib in Higher-Risk Myelodysplastic Syndromes in Brazil
2019-12-10 15:07:58 | Onconova Therapeutics, Inc. Announces Closing of $5.0 Million Registered Direct Offering Priced At-the-Market
2019-12-09 08:00:10 | Onconova Therapeutics, Inc. Announces $5.0 Million Registered Direct Offering Priced At-the-Market
2019-12-07 08:35:07 | The Week Ahead In Biotech: ASH Presentations Pick Up Steam, Correvio Awaits Adcom Ruling
2019-12-06 08:49:10 | Benzinga Pro's Top 5 Stocks To Watch For Fri., Dec. 6, 2019: TSLA, ONTX, XHB, BIG, SFIX
2019-12-06 07:30:10 | Inceptua Medicines Access and Onconova Therapeutics Announce Pre-approval Access Collaboration for Rigosertib in Selected Countries Outside the US
2019-11-25 09:26:13 | Onconova Therapeutics, Inc. Announces Closing of $11.0 Million Public Offering
2019-11-22 14:46:50 | Bucks County biopharm firm enters into licensing deal, embarks on stock sale
2019-11-21 11:23:16 | Onconova Therapeutics, Inc. Announces $11.0 Million Public Offering
2019-11-21 10:16:12 | Onconova Therapeutics Announces Exclusive License Agreement with Knight Therapeutics for Rigosertib in Canada